YMN-A02 treatment for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a new experimental drug called YMN-A02 for patients with advanced liver cancer (hepatocellular carcinoma) that has stopped responding to previous treatments. The drug may help slow or shrink the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced liver cancer that has progressed after prior anti-cancer treatments
- You are between 18 and 70 years old with good overall health (ECOG score 0-1)
- Your cancer has at least one measurable tumor visible on CT scan
- Your heart, liver, kidney, and blood cell counts are working well enough for treatment
- You have a life expectancy of at least 3 months
- You agree to follow study visits and cooperate with the research team
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination called MRG006A for people with advanced liver cancer (hepatocellular carcinoma) that cannot be removed by surgery or treated with local therapies. The goal is to see if it helps shrink tumors or slow cancer growth.
This trial tests combining Yttrium-90 microspheres (tiny radioactive beads delivered into the liver), immunotherapy (drugs that help your immune system fight cancer), and anti-angiogenesis drugs (medicines that block blood supply to tumors) followed by a liver-directed chemotherapy infusion. It is designed for people with hepatocellular carcinoma (liver cancer) that cannot be removed with surgery yet may become operable after this treatment.
This trial tests a new drug called BAY 3547926 for people with advanced liver cancer that cannot be removed with surgery or has not responded to other treatments. The goal is to see if the drug is safe and how well it works.
This trial tests a new medicine, PF-08634404, alone or with other treatments for adults with advanced liver cancer that cannot be removed by surgery or has spread. It is for people who have not had prior systemic therapy and have good liver function.
This trial tests a combination of immunotherapy (anti-PD-1/PD-L1) and an anti-VEGF drug for people with advanced hepatocellular carcinoma (HCC), a type of liver cancer that cannot be removed by surgery or has spread. The goal is to see if these drugs can shrink tumors or slow the cancer's growth.
This study tests a new medicine called YMN-A02 for colorectal cancer that has spread to the liver and does not respond well to standard treatments. The medicine uses a new technology to help your immune system fight the cancer.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.